{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T13:51:40Z","timestamp":1790085100150,"version":"4.0.1"},"reference-count":16,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T00:00:00Z","timestamp":1729209600000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"name":"Youth Science Foundation Project of Guangxi Natural Science Foundation","award":["2024GXNSFBA010284"],"award-info":[{"award-number":["2024GXNSFBA010284"]}]},{"name":"Guangxi Medical University Natural Science Youth Foundation","award":["GXMUYSF202431"],"award-info":[{"award-number":["GXMUYSF202431"]}]},{"name":"First-class discipline innovation-driven talent program of Guangxi Medical University"},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82370959"],"award-info":[{"award-number":["82370959"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Key Project of Guangxi Natural Science Foundation","award":["2023GXNSFDA026018"],"award-info":[{"award-number":["2023GXNSFDA026018"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["BMC Oral Health"],"DOI":"10.1186\/s12903-024-05036-5","type":"journal-article","created":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:02:56Z","timestamp":1729263776000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":6,"title":["Oral Lichenoid lesions induced by programmed cell death protein 1 and cytotoxic T-lymphocyte-associated protein 4 bispecific antibody: a case report"],"prefix":"10.1186","volume":"24","author":[{"given":"Qiaozhi","family":"Jiang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xinyu","family":"Chen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jiaxuan","family":"Wu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shanni","family":"Wei","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Renchuan","family":"Tao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2024,10,18]]},"reference":[{"issue":"2","key":"5036_CR1","doi-asserted-by":"publisher","first-page":"125","DOI":"10.1016\/j.currproblcancer.2016.12.001","volume":"41","author":"LK Collins","year":"2017","unstructured":"Collins LK, Chapman MS, Carter JB, Samie FH. Cutaneous adverse effects of the immune checkpoint inhibitors. Curr Probl Cancer. 2017;41(2):125\u20138.","journal-title":"Curr Probl Cancer"},{"issue":"7","key":"5036_CR2","doi-asserted-by":"publisher","first-page":"1484","DOI":"10.1093\/annonc\/mdx151","volume":"28","author":"MB Atkins","year":"2017","unstructured":"Atkins MB, Quinn JICDI. Immune checkpoint inhibitors in advanced renal cell carcinoma: experience to date and future directions. Annals Oncology: Official J Eur Soc Med Oncol. 2017;28(7):1484\u201394.","journal-title":"Annals Oncology: Official J Eur Soc Med Oncol"},{"issue":"21","key":"5036_CR3","doi-asserted-by":"publisher","first-page":"2020","DOI":"10.1056\/NEJMoa1910231","volume":"381","author":"MD Hellmann","year":"2019","unstructured":"Hellmann MD, Paz-Ares L, Bernabe Caro R, Zurawski B, Kim S-W, Carcereny Costa E, Park K, Alexandru A, Lupinacci L, de la Mora Jimenez E, et al. Nivolumab plus Ipilimumab in Advanced non\u2013small-cell Lung Cancer. N Engl J Med. 2019;381(21):2020\u201331.","journal-title":"N Engl J Med"},{"issue":"16","key":"5036_CR4","doi-asserted-by":"publisher","first-page":"1535","DOI":"10.1056\/NEJMoa1910836","volume":"381","author":"J Larkin","year":"2019","unstructured":"Larkin J, Chiarion-Sileni V, Gonzalez R, Grob J-J, Rutkowski P, Lao CD, Cowey CL, Schadendorf D, Wagstaff J, Dummer R, et al. Five-year survival with combined Nivolumab and Ipilimumab in Advanced Melanoma. N Engl J Med. 2019;381(16):1535\u201346.","journal-title":"N Engl J Med"},{"issue":"12","key":"5036_CR5","doi-asserted-by":"publisher","first-page":"1333","DOI":"10.1007\/s40265-022-01761-9","volume":"82","author":"SJ Keam","year":"2022","unstructured":"Keam SJ. Cadonilimab: first approval. Drugs. 2022;82(12):1333\u20139.","journal-title":"Drugs"},{"issue":"1","key":"5036_CR6","doi-asserted-by":"publisher","first-page":"e14703","DOI":"10.1111\/dth.14703","volume":"34","author":"V De Giorgi","year":"2021","unstructured":"De Giorgi V, Silvestri FSF, Maida P. Federico Venturi1, Luciana Trane, Alessia Gori: genital piercing: a warning for the risk of vulvar lichen sclerosus. Dermatol Ther. 2021;34(1):e14703.","journal-title":"Dermatol Ther"},{"issue":"5","key":"5036_CR7","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1158\/2159-8290.CD-20-1445","volume":"11","author":"SJ Dovedi","year":"2021","unstructured":"Dovedi SJ, Elder MJ, Yang C, Sitnikova SI, Irving L, Hansen A, Hair J, Jones DC, Hasani S, Wang B, et al. Design and efficacy of a Monovalent Bispecific PD-1\/CTLA4 antibody that enhances CTLA4 blockade on PD-1\u2009+\u2009activated T cells. Cancer Discov. 2021;11(5):1100\u201317.","journal-title":"Cancer Discov"},{"key":"5036_CR8","doi-asserted-by":"publisher","first-page":"36","DOI":"10.1016\/j.ctrv.2017.05.003","volume":"57","author":"JC Hassel","year":"2017","unstructured":"Hassel JC, Heinzerling L, Aberle J, B\u00e4hr O, Eigentler TK, Grimm M-O, Gr\u00fcnwald V, Leipe J, Reinmuth N, Tietze JK, et al. Combined immune checkpoint blockade (anti-PD-1\/anti-CTLA-4): evaluation and management of adverse drug reactions. Cancer Treat Rev. 2017;57:36\u201349.","journal-title":"Cancer Treat Rev"},{"key":"5036_CR9","doi-asserted-by":"crossref","unstructured":"Osias Vieira de Oliveira Filho ILG. Yuri De Lima Medeiros, Thiago Bueno De Oliveira, Nathaniel Simon Treister, Fabio Abreu Alves: oral and cutaneous immune- related adverse events in cancer patients: prevalence and overall survival. Oral Dis 2024.","DOI":"10.1111\/ODI.15056\/v3\/response1"},{"issue":"3","key":"5036_CR10","doi-asserted-by":"publisher","first-page":"345","DOI":"10.1007\/s40257-017-0336-3","volume":"19","author":"V Sibaud","year":"2017","unstructured":"Sibaud V. Dermatologic reactions to Immune Checkpoint inhibitors. Am J Clin Dermatol. 2017;19(3):345\u201361.","journal-title":"Am J Clin Dermatol"},{"issue":"2","key":"5036_CR11","doi-asserted-by":"publisher","first-page":"325","DOI":"10.1111\/odi.13218","volume":"26","author":"MA Shazib","year":"2020","unstructured":"Shazib MA, Woo SB, Sroussi H, Carvo I, Treister N, Farag A, Schoenfeld J, Haddad R, LeBoeuf N, Villa A. Oral immune-related adverse events associated with PD\u20101 inhibitor therapy: a case series. Oral Dis. 2020;26(2):325\u201333.","journal-title":"Oral Dis"},{"issue":"2","key":"5036_CR12","doi-asserted-by":"publisher","first-page":"230","DOI":"10.1016\/j.jobcr.2018.02.003","volume":"9","author":"DS Sanketh","year":"2019","unstructured":"Sanketh DS, Kumari K, Rao RS, Haragannavar VC, Sarode SC, Sarode GS, Raj AT, Patil S. Expression of Ki-67, p53, \u03b1-SMA and COX-2 in lichen planus and related lesions: a pilot study. J Oral Biology Craniofac Res. 2019;9(2):230\u20135.","journal-title":"J Oral Biology Craniofac Res"},{"issue":"3","key":"5036_CR13","doi-asserted-by":"publisher","first-page":"152072","DOI":"10.1016\/j.imbio.2021.152072","volume":"226","author":"TM Ferrisse","year":"2021","unstructured":"Ferrisse TM, de Oliveira AB, Pala\u00e7on MP, Silva EV, Massucato EMS, de Almeida LY, L\u00e9on JE, Bufalino A. The role of CD68\u2009+\u2009and CD163\u2009+\u2009macrophages in immunopathogenesis of oral lichen planus and oral lichenoid lesions. Immunobiology. 2021;226(3):152072.","journal-title":"Immunobiology"},{"issue":"3","key":"5036_CR14","doi-asserted-by":"publisher","first-page":"1259","DOI":"10.1111\/odi.14112","volume":"29","author":"M Lodolo","year":"2022","unstructured":"Lodolo M, Gobbo M, Bussani R, Torelli L, Rupel K, Ottaviani G, Poropat A, Biasotto M. Histopathology of oral lichen planus and oral lichenoid lesions: an exploratory cross-sectional study. Oral Dis. 2022;29(3):1259\u201368.","journal-title":"Oral Dis"},{"key":"5036_CR15","doi-asserted-by":"crossref","unstructured":"Carrozzo M, Porter S, Mercadante V, Fedele S. Oral lichen planus: A disease or a spectrum of tissue reactions? Types, causes, diagnostic algorhythms, prognosis, management strategies. Periodontology 2000 2019(80):105\u2013125.","DOI":"10.1111\/prd.12260"},{"issue":"28","key":"5036_CR16","doi-asserted-by":"publisher","first-page":"2872","DOI":"10.1200\/JCO.2018.79.0006","volume":"36","author":"C Kathryn","year":"2018","unstructured":"Kathryn C, Arbour LM, Niamh L, Rizvi H, Auclin E, Ni A, Mart\u00b4\u0131nez-Bernal G, Ferrara R, Victoria Lai W, Lizza EL, Hendriks JK, Sabari C, Caramella AJ, Plodkowski D, Halpenny JE, Chaft D, Planchard GJ, Riely. Benjamin Besse, and Matthew D. Hellm: impact of baseline steroids on efficacy of programmed cell Death-1 and programmed death-ligand 1 blockade in patients with non\u2013small-cell Lung Cancer. J Clin Oncol. 2018;36(28):2872\u20138.","journal-title":"J Clin Oncol"}],"container-title":["BMC Oral Health"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-024-05036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12903-024-05036-5\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12903-024-05036-5.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,18]],"date-time":"2024-10-18T15:03:47Z","timestamp":1729263827000},"score":1,"resource":{"primary":{"URL":"https:\/\/bmcoralhealth.biomedcentral.com\/articles\/10.1186\/s12903-024-05036-5"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,10,18]]},"references-count":16,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2024,12]]}},"alternative-id":["5036"],"URL":"https:\/\/doi.org\/10.1186\/s12903-024-05036-5","relation":{},"ISSN":["1472-6831"],"issn-type":[{"value":"1472-6831","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,18]]},"assertion":[{"value":"15 August 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"9 October 2024","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"18 October 2024","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Not applicable.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethics approval and consent to participate"}},{"value":"A written informed consent for publication was obtained from the patient to publish all clinical details and any accompanying images.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent for publication"}},{"value":"The authors declare no competing interests.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"1240"}}